Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented City Therapeutics in the transaction. City Therapeutics, a biopharmaceutical company, announced raising $135 million in Series A financing...
City Therapeutics’ $135 Million Series A Financing Round
Edwards Lifesciences’ Acquisition of JenaValve
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented JenaValve Technology in the transaction. Involved fees earner: Heather Aune – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;...
AtaCor Medical’s $28 Million Series C Financing Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented AtaCor Medical in the transaction. AtaCor Medical (“Atacor”) announced it raised $28 million in Series C financing round...
Xaira Therapeutics’ $1 Billion Funding
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Xaira Therapeutics in the transaction. Xaira Therapeutics (Xaira), an AI biotechnology company, from formation and through $1 billion...
Tarsus Pharmaceuticals’ $115.0 Million Common Stock Offering
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian acted as counsel to Tarsus Pharmaceuticals in the offering, Hogan Lovells acted as regulatory counsel while Knobbe Martens Olson...
Viridos’ $25 Million Series A Financing
Gunderson Dettmer represented Viridos on the deal. Viridos, the leading algae biofuel company, announced its $25 million Series A financing led by Breakthrough Energy Ventures (BEV) and...
BigHat’s $75 Million Series B Financing
Gunderson Dettmer represented client Section 32 on the deal while Wilson Sonsini advised BigHat Biosciences. Section 32, a venture capital fund that invests in frontiers of...